Tilray Brands, Inc. (TLRY)
USD 0.49
(-3.98%)
USD 0.49
(-3.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 158.97 Million USD | -58.55% |
| 2023 | 383.49 Million USD | 84.47% |
| 2022 | 207.89 Million USD | -53.82% |
| 2021 | 450.19 Million USD | 874.22% |
| 2020 | -58.14 Million CAD | -26.48% |
| 2019 | -45.97 Million CAD | -106.92% |
| 2018 | -22.21 Million CAD | 35.6% |
| 2017 | -34.5 Million CAD | -173.19% |
| 2016 | -12.62 Million CAD | -122.58% |
| 2015 | -5.67 Million CAD | -58111.37% |
| 2014 | -9747.68 CAD | 59.1% |
| 2013 | -23.83 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 386 Million USD | 0.21% |
| 2024 FY | 158.97 Million USD | -58.55% |
| 2024 Q4 | 158.97 Million USD | -52.6% |
| 2024 Q1 | 385.19 Million USD | 0.44% |
| 2024 Q3 | 335.36 Million USD | -13.12% |
| 2023 Q3 | 438.73 Million USD | 4.79% |
| 2023 Q1 | 167.17 Million USD | -19.59% |
| 2023 Q2 | 418.69 Million USD | 150.45% |
| 2023 Q4 | 383.49 Million USD | -12.59% |
| 2023 FY | 383.49 Million USD | 84.47% |
| 2022 Q2 | 467.98 Million USD | -5.92% |
| 2022 Q4 | 207.89 Million USD | -54.17% |
| 2022 FY | 207.89 Million USD | -53.82% |
| 2022 Q1 | 497.43 Million USD | 10.49% |
| 2022 Q3 | 453.65 Million USD | -3.06% |
| 2021 Q2 | 276.89 Million CAD | 1368.94% |
| 2021 Q1 | 18.84 Million CAD | 132.42% |
| 2021 Q3 | 519.16 Million CAD | 87.5% |
| 2021 FY | 450.19 Million USD | 874.22% |
| 2021 Q4 | 450.19 Million USD | -13.29% |
| 2020 Q2 | 5.85 Million CAD | -68.42% |
| 2020 Q3 | -22.38 Million CAD | -481.95% |
| 2020 Q4 | -58.14 Million CAD | -159.81% |
| 2020 Q1 | 18.55 Million CAD | 140.36% |
| 2020 FY | -58.14 Million CAD | -26.48% |
| 2019 Q4 | -45.97 Million CAD | -100.66% |
| 2019 FY | -45.97 Million CAD | -106.92% |
| 2019 Q2 | -72.99 Million CAD | 56.34% |
| 2019 Q3 | -22.91 Million CAD | 68.61% |
| 2019 Q1 | -167.18 Million CAD | -652.48% |
| 2018 FY | -22.21 Million CAD | 35.6% |
| 2018 Q3 | -63.23 Million CAD | 2.56% |
| 2018 Q4 | -22.21 Million CAD | 64.86% |
| 2018 Q2 | -64.89 Million CAD | -1451.6% |
| 2018 Q1 | -4.18 Million CAD | 87.88% |
| 2017 Q3 | -57.28 Million CAD | 15.49% |
| 2017 Q1 | -34.92 Million CAD | -176.56% |
| 2017 Q2 | -67.78 Million CAD | -94.05% |
| 2017 Q4 | -34.5 Million CAD | 39.77% |
| 2017 FY | -34.5 Million CAD | -173.19% |
| 2016 Q1 | -3.88 Million CAD | 31.6% |
| 2016 Q2 | -2.45 Million CAD | 36.68% |
| 2016 Q4 | -12.62 Million CAD | -41.99% |
| 2016 FY | -12.62 Million CAD | -122.58% |
| 2016 Q3 | -8.89 Million CAD | -261.96% |
| 2015 Q3 | -7.38 Million CAD | -6556.29% |
| 2015 Q2 | -110.97 Thousand CAD | -835.88% |
| 2015 Q1 | -11.85 Thousand CAD | -76.86% |
| 2015 FY | -5.67 Million CAD | -58111.37% |
| 2015 Q4 | -5.67 Million CAD | 23.19% |
| 2014 Q4 | -6704.57 CAD | 40.9% |
| 2014 Q3 | -11.34 Thousand CAD | -490.72% |
| 2014 Q2 | -1920.54 CAD | 80.3% |
| 2014 Q1 | -9747.68 CAD | -601.59% |
| 2014 FY | -9747.68 CAD | 59.1% |
| 2013 Q1 | -23.83 Thousand CAD | 41.82% |
| 2013 Q4 | -1389.37 CAD | 90.89% |
| 2013 FY | -23.83 Thousand CAD | 0.0% |
| 2013 Q3 | -15.24 Thousand CAD | 30.29% |
| 2013 Q2 | -21.87 Thousand CAD | 8.23% |
| 2012 Q2 | -64.46 Thousand CAD | 0.0% |
| 2012 Q3 | -46.38 Thousand CAD | 28.05% |
| 2012 Q4 | -40.96 Thousand CAD | 11.68% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -8531.967% |
| Alpha Teknova, Inc. | 1.97 Million USD | -7953.546% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -68.753% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -112.111% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 63.482% |
| Cosmos Health Inc. | 8.59 Million USD | -1750.559% |
| Journey Medical Corporation | -9.7 Million USD | 1737.419% |
| Embecta Corp. | 1.31 Billion USD | 87.883% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 65.342% |
| Dynavax Technologies Corporation | 106.63 Million USD | -49.085% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 221.515% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 63.263% |
| PainReform Ltd. | -7.95 Million USD | 2099.711% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 1116.825% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 1116.825% |
| SCYNEXIS, Inc. | -19.35 Million USD | 921.587% |
| Safety Shot Inc | -2.28 Million USD | 7059.321% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1785.912% |
| Procaps Group, S.A. | 242.93 Million USD | 34.559% |
| Theratechnologies Inc. | 24.87 Million USD | -539.206% |
| Harrow Health, Inc. | 116.41 Million USD | -36.558% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 6408.611% |
| Biofrontera Inc. | 4.05 Million USD | -3819.551% |
| DURECT Corporation | -7.65 Million USD | 2177.045% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 574.176% |
| Cronos Group Inc. | -663.32 Million USD | 123.967% |
| OptiNose, Inc. | 58.06 Million USD | -173.791% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 74.498% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 1190.976% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 3165.485% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -958.929% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 2599.778% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -148672.682% |
| Radius Health, Inc. | 359.28 Million USD | 55.751% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -80513.461% |
| ProPhase Labs, Inc. | 19.23 Million USD | -726.67% |
| Phibro Animal Health Corporation | 454.84 Million USD | 65.048% |
| Procaps Group S.A. | 242.93 Million USD | 34.559% |
| Alvotech | 1.06 Billion USD | 85.063% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -4222.376% |
| Viatris Inc. | 17.13 Billion USD | 99.072% |
| Rockwell Medical, Inc. | 4.45 Million USD | -3467.706% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 3359.729% |
| SIGA Technologies, Inc. | -148.68 Million USD | 206.924% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -30.418% |
| Shineco, Inc. | 29.29 Million USD | -442.763% |
| PetIQ, Inc. | 351.93 Million USD | 54.827% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 5579.267% |
| Incannex Healthcare Limited | -5.48 Million USD | 2998.396% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 10.334% |
| Alimera Sciences, Inc. | 55.3 Million USD | -187.434% |
| Silver Spike Investment Corp. | -32.61 Million USD | 587.486% |
| Assertio Holdings, Inc. | -32.52 Million USD | 588.724% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 10778.757% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 3241.6% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 3402.389% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 2035.563% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -3669.908% |
| Hempacco Co., Inc. | 13.61 Million USD | -1067.688% |
| Talphera, Inc. | -5.72 Million USD | 2878.832% |
| Alvotech | 1.06 Billion USD | 85.063% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -2125.01% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 264.385% |
| Currenc Group, Inc. | -16.57 Million USD | 1059.246% |
| Kamada Ltd. | -46.43 Million USD | 442.39% |
| Indivior PLC | -33.95 Million USD | 568.241% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -60910.308% |
| Flora Growth Corp. | -713 Thousand USD | 22396.914% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 2035.563% |
| Evolus, Inc. | 63.7 Million USD | -149.54% |
| HUTCHMED (China) Limited | -197.45 Million USD | 180.512% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 66.818% |
| Akanda Corp. | 3.9 Million USD | -3971.202% |